FMP
Summit Therapeutics Inc.
SMMT
NASDAQ
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
23.96 USD
-0.685 (-2.86%)
Historical Prices
From:
To:
About
ceo
Mr. Robert W. Duggan
sector
Healthcare
industry
Biotechnology
website
https://www.summittxinc.comexchange
NASDAQ
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cam...
CIK
0001599298
ISIN
US86627T1088
CUSIP
86627T108
Address
One Broadway
Phone
617 514 7149
Country
US
Employee
159
IPO Date
Mar 5, 2015
Financial Statement
Earnings
SMMT Financial Summary
CIK
0001599298
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
86627T108
ISIN
US86627T1088
Country
US
Price
23.96
Beta
-0.95
Volume Avg.
4.04M
Market Cap
17.67B
Shares
-
52-Week
2.1-36.91
DCF
0.18
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-70.47
P/B
-
Website
https://www.summittxinc.com
Upgrades and Downgrades
Rating Distribution
TheFly
11 days ago
Apr 28, 2025
Buy
Buy
TheFly
14 days ago
Apr 25, 2025
Buy
Buy
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SMMT News
Andrew Wynn
Apr 25, 2025
Summit Therapeutics Inc. (NASDAQ: SMMT) Sees Promising Futur...
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical company focused on developing innovative therapies for serious diseases. Recently, Kelly Shi from Jefferies set a price target of $44 for SMMT, while the stock was trading at $25.61. This suggests a potential increase of approximately 71.84%, indicating strong confidence in the company's future performance. Summit is set to host an earnings call on May 1, 2025, to discuss its first quarter 2025 financial results and provide an opera...
24/7 Wall Street
Aug 8, 2024
3 Small-Cap Stocks That Could Outperform the “Magnificent 7”
Recent headlines have highlighted the shift many investors are making from large-cap to small cap stocks.
Seeking Alpha
Aug 3, 2024
Summit Therapeutics May Have Further Upside From Here
Summit Therapeutics to release second-quarter earnings and operational update on 6 August. Analysts are bullish on Phase 3 trial results for Ivonescimab in September, with a potential de-risking of the drug's profile. The company boosted its balance sheet with a $200 million institutional capital raise and expanded licensing territories after positive Phase I and II trial results.
The Motley Fool
Jun 17, 2024
3 Stocks That Have Soared 179% or More in 2024 and Could Go ...
These three stocks have soared between 179% and 220% so far this year. Wall Street thinks they can all jump at least 20% over the next 12 months.
Zacks Investment Research
Jun 12, 2024
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Schaeffers Research
May 31, 2024
Biotech Stock Volatile After Upbeat Trial data
The shares of Summit Therapeutics Inc (NASDAQ:SMMT) appear to be headed for a minor correction after yesterday's skyrocket.
Reuters
May 30, 2024
Summit Therapeutics cancer therapy succeeds in late-stage Ch...
Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China.
The Motley Fool
May 28, 2024
Why Summit Therapeutics Stock Is Sinking Today
Summit Therapeutics' stock is falling sharply for the second consecutive trading day. The sell-off began after the company revealed disappointing late-state data for its lead pipeline candidate.
